通过协同生物标志物和人体血清代谢物优化糖尿病病的早期检测
Xianke Zhou1,2, Yuan Gui3, Jia-Jun Liu4
1State Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Diabetes & metabolism journal
|January 28, 2026
概括
通过将MMP-7和TNC等生物标志物与血清代谢物结合起来,可以改善糖尿病病 (DKD) 的早期检测. 这种方法有助于识别2型糖尿病 (T2DM) 患者的微妙损伤.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 生物标志物发现发现
- 代谢学 代谢学 代谢学
背景情况:
- 糖尿病病 (DKD) 构成重大威胁,由于高血糖和早期通路激活,其进展迅速.
- 早期发现DKD对于在明显的临床症状出现之前识别微妙的损伤至关重要.
研究的目的:
- 通过将人体血清蛋白质组与单细胞RNA测序和空间转录组数据相结合,确定早期DKD诊断的关键生物标志物.
- 开发用于DKD早期检测的机器学习算法,使用协同生物标志物和血清代谢物.
主要方法:
- 结合人类血清蛋白质组学,单细胞RNA测序和空间转录组学数据.
- 从健康成年人和2型糖尿病患者 (T2DM) 的血清中分析了使用代谢学和ELISA的血清.
- 在多个临床队伍中开发和验证机器学习算法.
主要成果:
- 甲蛋白酶-7 (MMP-7) 和素C (TNC) 在人类糖尿病脏和DKD患者血清中升高.
- 血清粉样蛋白A1 (SAA1) 和TNC在DKD患者的血清中上调.
- 将MMP-7,SAA1和TNC与血清代谢物结合在一起的算法,提高了大约13%的早期DKD检测准确度.
结论:
- 将协同作用的生物标志物与血清代谢学相结合,可显著提高早期DKD检测.
- 这种综合方法有可能通过减缓疾病进展来改善T2DM患者的治疗结果.
相关概念视频
01:25Chronic Kidney Disease I: Introduction
725
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
725
01:24Chronic Kidney Disease II: Clinical Manifestations
641
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
641
01:28Chronic Kidney Disease III: Interprofessional Care
466
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
466
01:18Chronic Kidney Disease IV: Nursing Management
388
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
388
01:45Kidney Structure
75.1K
The kidneys are two large bean-shaped organs located in the upper abdomen. They filter the blood several times a day to remove toxins and rebalance water and electrolytes of the circulatory system via the renal veins. The kidneys receive blood directly from the heart via the renal arteries. These arteries enter the kidney at the hilum, the concave surface of the bean, where they branch and divide into smaller vessels and capillaries.
75.1K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
228
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
228